The objective of the present meta–analysis was to analyze efficacy and safety of postoperative chemoradiotherapy (CRT) and establish a consensus on whether it is suitable for the patients.

From the results of the study, postoperative adjuvant CRT may be associated with longer 5–year overall survival (OS) and 5–year RFS in patients with D2 lymphadenectomy, but might not improve 5–year disease–free survival compared to non–CRT. Methodologically high–quality comparative studies are needed for further evaluation.

READ FULL ARTICLE Curated publisher From Mdlinx